Compass Pathways Says Final Psilocybin Application Is Due Within Two Weeks, Targets First-Half 2027 Launch
The drug developer reported $444.0 million in cash, which it says lasts into 2028, as a $40.8 million warrant gain cut its quarterly loss.
Compass Pathways, a biotechnology company developing an investigational psilocybin treatment called COMP360 for depression and PTSD, said it will file the last piece of its FDA application within two weeks. The company expects a launch in the first half of 2027, subject to FDA approval, it said Tuesday in its third-quarter results.
A loss shrunk by a warrant gain
Compass reported a third-quarter net loss of $9.8 million, or $0.07 a basic share, against $137.7 million a year earlier. The company attributed the narrower loss mainly to non-cash fair-value changes on its warrants: a $40.8 million gain this quarter, versus a $101.3 million loss in the year-earlier quarter.
The operating picture moved the other way. Operating loss widened to $56.4 million from $40.5 million. Selling, general and administrative spending rose to $33.0 million from $13.2 million, which the company tied to launch preparation, including commercial infrastructure, market access and reimbursement, and supply chain readiness.
Research and development spending fell to $23.5 million from $27.3 million, as clinical trial costs dropped after the Phase 3 program in treatment-resistant depression finished. For the first nine months, the net loss was $172.4 million, compared with $194.0 million a year earlier.
Cash of $444.0 million, debt of $51.0 million
Cash and equivalents stood at $444.0 million on September 30, up from $149.6 million at the end of 2025. Debt was $51.0 million, up from $31.6 million. The company said the cash should cover operating expenses and capital spending into 2028, which it described as well beyond launch.
Shares outstanding rose to 141,684,353 from 96,085,785 at year-end.
The case for a depression launch
Treatment-resistant depression means depression that has not responded adequately to two or more antidepressant courses. Compass estimates 4 million people in the U.S. live with it, and says the only marketed medicine has captured under 3% market share.
The company says 52-week open-label data from one Phase 3 trial showed added benefit from an extra 25 mg dose, extending durability to one year. It argues COMP360 could offer durable benefit from a few treatments a year, and expects it to fit into more than 8,500 treatment centers already equipped to deliver multi-hour treatments.
CEO Kabir Nath said the company is "executing with urgency and discipline" toward a first-half 2027 launch. Compass says a National Priority Voucher could cut review time to 1-2 months, and that a White House executive order directs the Drug Enforcement Administration to review rescheduling promptly. Its sales team selection is underway, and a late-stage PTSD trial is ongoing.
The final submission is due within two weeks of Tuesday's report, after which the FDA review and any DEA rescheduling stand between Compass and its first-half 2027 target.
Sources
- 8-K Filing — COMPASS Pathways plc (CMPS) — SEC EDGAR
- Exhibit q32026pressrelease.htm — COMPASS Pathways plc 8-K exhibit — SEC EDGAR
- Compass points to unmet need as psychedelic nears market — fiercepharma.com
- Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights – Company Announcement - FT.com — Financial Times